ADCs : antibodies and cytotoxic molecules united against tumours
Contexte historique des ADC L’histoire des immuno-conjugués appelés Antibody-Drug Conjugate ou ADC en anglais, ces biomédicaments révolutionnaires en oncologie, remonte aux travaux visionnaires de Paul Ehrlich, un scientifique allemand du début du 20ème siècle. Paul Ehrlich est souvent considéré comme le père de l’immunologie moderne et de la chimiothérapie. Son concept de « balle magique […]
Antibody-oligonucleotides conjugates
Each month, MabDesign’s market analyses give you an overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market for biomedicines and biomanufacturing. This month, an overview of antibody-oligonucleotide conjugate (AOC) projects currently in development.
Experts’ corner : Cell therapies
The Experts Corner – Read our interview with Sophie Derenne from the EFS, on the cell therapy market, its challenges and prospects.
Gene therapies
This month’s MabDesign market analysis gives you an overview of the gene therapy market and projects currently in development.
Bioproduction of viral vectors: challenges, innovations and market prospects
Viral vectors are essential therapeutic tools for gene therapy and certain vaccines. The growing number of cell and gene therapy products on the market means that the production of viral vectors is an increasingly strategic sector.
Respiratory syncitial virus
This month’s MabDesign market analysis gives you an overview of market dynamics and projects in development targeting respiratory syncitial virus (RSV).
Biomanufacturing of biological drugs: strategic issues and challenges
Biomanufacturing, or the manufacturing phase of innovative biological medicines, is a rapidly expanding field that is essential for meeting modern healthcare needs and represents a major strategic challenge. Faced with growing dependence on imports and increasing international competition, there are many technological and industrial challenges to developing this sector. In France, major efforts are being made, notably through the France 2030 plan, to ensure pharmaceutical sovereignty and meet future medical needs. This article explores the challenges and opportunities presented by biomanufacturing.
Infectious diseases
This month, MabDesign’s market analysis gives you an overview of projects in development in the field of infectious diseases.
breast cancer
The MabDesign market analysis for this month of pink October gives you an overview of market dynamics and projects in development targeting the treatment of breast cancer.
Multiple Sclerosis
This month’s MabDesign market analysis gives you an overview of market dynamics and development projects targeting the treatment of multiple sclerosis.
The immuno-oncology market
Long considered as cellular debris with no biological function, exosomes, and more generally extracellular vesicles (EVs), are now recognized as vectors of biological material with a role in intercellular communication. The building of knowledge on the subject has not only highlighted their role in certain pathologies, but also revealed their potential as biomarkers and therapeutic tools.
The beginnings of cell culture
Cell culture is the cornerstone of biomedical research and biotechnology innovation. Although the bioproduction of biomedicines in bioreactors is now the norm, and the use of organoids and “organ-on-a-chip” (OoC) is growing, the beginnings of in vitro cell culture were more modest.
Glioblastoma
This month’s MabDesign market analysis gives you an overview of market dynamics and pipeline projects targeting the glioblastoma.
Exosomes and extracellular vesicles
Long considered as cellular debris with no biological function, exosomes, and more generally extracellular vesicles (EVs), are now recognized as vectors of biological material with a role in intercellular communication. The building of knowledge on the subject has not only highlighted their role in certain pathologies, but also revealed their potential as biomarkers and therapeutic tools.
Bispecific antibodies
This month’s MabDesign market analysis gives you an overview of market dynamics and development projects targeting melanoma treatment.
Melanoma
This month’s MabDesign market analysis gives you an overview of market dynamics and development projects targeting melanoma treatment.
Cell and gene therapies
The first edition of our Innovations for Cell and Gene Therapies (ICGT) congress, organized in collaboration with the Société Française de Thérapie Cellulaire et génique (SFTCG), will take place on May 22, 2024, in Paris. In the meantime, this month we share an overview of the cell and gene therapy market.
Advanced therapy medicinal products: from the lab to the patient’s bed
Advanced therapy medicinal products (ATMPs) explore new therapeutic approaches based on genome modification, manipulation of patient or healthy donor cells and other innovative methods, representing a major transition from traditional medicine to more personalized and targeted medicine.
The history of biologics: from discovery to therapeutic revolution
Biopharmaceuticals, or biotherapies, are becoming increasingly important on the market, and offer immense hope for the treatment of many diseases. From the first discoveries of vaccines to the recent development of cell and gene therapies and regenerative medicine, looking back at biologics’ history lets us have a better understanding of the revolution that they provoked in the pharmaceutical industry and in modern medicine .
Therapeutic vaccines in oncology
This month, MabDesign’s market analysis provides an overview of the market for therapeutic oncology vaccines.
antibody-drug conjugates
This month’s MabDesign market analysis gives you an overview of the antibody-drug conjugates market and projects in development.
Prophylactic or Therapeutic : what does the future hold for vaccines ?
Fuelled by decades of innovation, vaccines are an essential tool in the fight against disease. Historically focused on prophylaxis to prevent the spread of infectious diseases, new generations of vaccines are now being developed and/or are already available in other therapeutic areas including oncology. Historically focused on prophylaxis and infectious diseases, they are now opening up to new avenues of development, with a range of vaccine technologies, the positioning of vaccines as a new therapeutic tool, and the opening up of other therapeutic areas such as oncology.
Monoclonal antibodies: the stars of therapeutic proteins
Hybridoma technology for the production of monoclonal antibodies (mAbs), awarded the Nobel Prize for Medicine in 1984, revolutionized serotherapy, which previously used patient serum containing mixtures of antibodies. More targeted and therefore more effective, mAbs offer innovative perspectives in the treatment of various diseases, and have become an essential therapeutic strategy in our pharmaceutical arsenal.
Neurological disorders
This month’s market analysis by MabDesign gives you an overview of market dynamics and projects in development targeting neurological disorders.
